News

  1. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial Of AeroVanc For MRSA Lung Infection In Cystic Fibrosis Patients
    4/18/2013

    Savara Pharmaceuticals announced today that the first patient has started study drug treatment in a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients.

  2. Ablynx's Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety And Efficacy Results In A Phase II Clinical Trial In Rheumatoid Arthritis
    2/13/2013

    Ablynx (EURONEXT BRUSSELS: ABLX) today announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week final analysis of the Phase II part of a combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.

  3. ERT, Johns Hopkins University And The University Of Washington Expand Study On Effects Of Home-Health Monitoring On Exacerbations Of Cystic Fibrosis
    2/4/2013

    ERT, a global technology-driven provider of health outcomes research services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), along with pulmonary researchers at the Johns Hopkins University School of Medicine  and University of Washington, recently announced an expansion to the Early Intervention in Cystic Fibrosis Exacerbation (eICE) Study.

  4. Portola And Lee's Pharmaceutical Enter Into Agreement To Expand Phase 3 APEX Study Of Betrixaban Into China
    1/29/2013

    Portola Pharmaceuticals, Inc. and Lee's Pharmaceutical (HK) Ltd. (HKSE: 0950) today announced an agreement to jointly expand the Phase 3 APEX study of betrixaban into China, with an option for Lee's to negotiate for the commercial rights to the drug in China.

  5. ERT Announces Agenda, Faculty For Annual Conference
    1/18/2013

    ERT, a global technology-driven provider of health outcomes research services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), has provided updated information on PROFICIENCY 2013:  Maximizing Product Value with Optimized Endpoints, its 6th annual educational conference.

  6. ERT Expands Corporate Presence In Japan
    1/15/2013

    ERT, a global technology-driven provider of health outcomes research services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), recently announced significant milestones that reinforce its position as a leading eClinical trial solutions provider in Japan.

  7. Astrazeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
    12/13/2012

    AstraZeneca recently announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

  8. Theravance Announces Initiation Of Phase 2b Study With Its LAMA Candidate, TD-4208, For The Treatment Of COPD
    12/11/2012

    Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD.

  9. Dynavax To Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
    10/31/2012

    Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies.

  10. Novartis To Start Construction Of New Biotechnology Facility In Singapore With An Investment Of Over USD 500 Million
    10/31/2012

    ​Novartis announced recently the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology.